ECCO 2023

JAK inhibitors - small molecules to treat IBD

New molecules on the horizon!

S1P modulators - a rising class of drugs

A focus on surgery and post-operative maintenance

Medium-term outcome of IBD patients diagnosed at preclinical stage

No impact of previous therapies for Upadacitinib in Crohn's disease

Vedolizumab heals pouch mucosa

Latest update on JAK inhibition

Prolonged treatment with Ozanimod recaptures remission in about 1/3 of UC patients not responding at week 10

S1P modulators in UC

Long-term extension of ustekinumab in UC

Upadacitinib is efficacious for UC regardless of biologic pretreatment

Mucosal healing induced by vedolizumab in chronic pouchitis

Long-term duration of response with ozanimod in UC

Upadacitinib works in bionaive and bio-exposed pts in CD and UC

Upadacitinib for fistulizing Crohn´s disease?

Lang Termijn respons met ozanimod bij colitis ulcerosa

S1P-Modulatoren bei Colitis ulcerosa

Studio lungo termine di ustekinumab in UC

Il prolungamento del trattamento con Ozanimod induce remissione clinica in circa 1/3 dei pazienti trattati e che non hanno mostrato risposta clinica entro le prime 10 settimane

Upadacitinib: Vortherapien spielen keine Rolle mehr bei Morbus Crohn

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που διαγιγνώσκονται σε προκλινικό στάδιο

Update zu JAK-Inhibitoren bei CED

Upadacitinib is efficient bij colitis ulcerosa, ongeacht eerdere blootstelling aan biologische therapieen

Anti-IL23 drugs: is it all the same?

Safety update on JAKis - new worries?

S1P-modulators: a spotlight on safety

New aspects on safety of anti-TNF treatment

Ileostomy with better prognosis than pouch in PSC

Risk of IBD from early antibiotic exposure in live

Positive effects of Upadacitinib on resolution of abdominal symptoms and normalization of fatigue in active UC pts

Ozanimod shows good efficacy and safety profile in UC patients after 2 and 3 years of treatment

Etrasimod shows fast stool frequency and rectal bleeding normalization in UC patients

Ozanimod shows good efficacy and safety profile after 2&3 years of treatment

Το upadacitinib επιφέρει ύφεση των κοιλιακών συμπτωμάτων και αποκατάσταση της χρόνιας κόπωσης σε ασθενείς με ενεργό ελκώδη κολίτιδα

Ileostomie mit besserer Prognose als Pouch bei PSC

Rapido controllo del sanguinamento rettale e della frequenza evacuativa in pazienti affetti da RCU trattati con Etrasimod

Les antibiotiques dans la petite enfance augmentent le risque de maladie de Crohn pédiatrique

Practice-changing data on surgery in CD and UC

10 years of Tofacitinib – still more lessons to learn

Postoperative recurrence in CD

Is it feasible to stop anti-TNF treatment in combinational therapies in IBD?

Peri- and postoperative management of CD

Biologics in CD – is earlier better?

Timing of surgery in Crohn's disease

Ileocaecal Crohn's disease - should we call the surgeon first?

Surgical and post-operative management in CD

DNA methylation predicts response to biologics in IBD

Enteral nutrition - food for thought!

Vedolizumab for preventing postoperative reccurence of CD

Early treatment with biologics in IBD

Surgery in CD - resetting or not?

Epigenetic fingerprinting - a novel tool for precision medicine in IBD

New drugs on the block!

Another clue for the role of the microbiome in PSC?

Vedolizumab prevents postoperative recurrence in CD

Post-surgical Crohn's disease

Neue Substanzen!

Peri- und postoperatives Management bei Morbus Crohn

Vedolizumab previene la recidiva post operatoria nei pazienti con malattia di Crohn

Postać ileocekalna choroby Crohna - czy chirurgia ma pierwszeństwo?

Biologics in CD - is earlier better?

Biosimilars

Chirurgischer Verlauf nach Morbus Crohn

Another clue for the role of the microbiome in PSC?

Vedolizumab en prévention de la récidive postopératoire de la MC

Aanpak van de (post)operatieve Crohn patient

Résection chirurgicale au course de la maladie de Crohn: une remise a zéro ou pas?

Résection chirurgicale précoce dans la MC

Epigenetic Fingerprinting - ein neues Werkzeug für die Präzisionsmedizin bei CED

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες από τη συνδυασμένη θεραπείας τους με κλασικά ανοσοκατασταλτικά

Comprehensive remission - the new standard!?

Histology - a new therapeutic target in UC?

Disease clearance induced by etrasimod in UC

Comprehensive Disease Control

Comprehensive Disease Control

New opportunities from the application of artificial intelligence (AI) to the new endoscopic technologies

Sequencing in IBD - congress overview

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

Comprehensive overview of surgery in IBD

GPX4 fueling postoperative recurrence in Crohn's disease

Our patients will be better off in the near future!

New ECCO guidelines on extraintestinal manifestations in IBD

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Nuove opportunità dall’applicazione dell’intelligenza artificiale alle nuove tecniche endoscopiche

Sequencing nelle malattie infiammatorie cronicale intestinali

Panoramica completa sulla chirurgia nelle malattie infiammatorie cronicale intestinali

Nowe wytyczne ECCO dotyczące manifestacji pozajelitowych w IBD

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

Una vida mejor en el futuro inmediato para nuestros pacientes